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ABSTRACT
Background. Epidermal growth factor receptor (EGFR)
signaling is one of the most promising targets for molec-
ular-targeted therapies in esophageal squamous cell
carcinoma (ESCC). Thus, the molecular diagnosis of KRAS
and BRAF mutations is clinically important in therapeutic
decision making. However, the frequency of KRAS and
BRAF mutations in ESCCs remains inconclusive because
of the limited sample sizes of previous studies (all
N B 80). Pyrosequencing is a nonelectrophoretic nucleo-
tide extension sequencing technology that can be used for
mutation testing.
Methods. The frequency of KRAS and BRAF mutations
was examined using a nonbiased database of 203 resected
ESCCs and a high-throughput pyrosequencing assay.
Results. The validity of the KRAS pyrosequencing method
was initially demonstrated by detection of all 4 types of KRAS
mutations [c.35G[T (codon 12 GGT[GTT), c.35G[A
(codon 12 GGT[GAT), c.34G[T (codon 12 GGT[TGT),
c.38G[A mutation (codon 13 GGC[GAC)], which had been
previously diagnosed using Scorpion-ARMS technology, in 9
colon cancer tissues (9 of 9; 100 %). Similar results were
demonstrated for BRAF mutational status in 3 colon cancer
cell lines (HCT116, Colo201, and HT29), which were vali-
dated by Sanger dideoxy sequencing. Subsequently, the KRAS
mutation was found to be extremely rare (1 of 203; 0.5 %), and
the BRAF mutation was absent (0 of 203; 0 %), in the dataset
of 203 ESCCs.
Conclusions. These results suggest that KRAS and BRAF
mutations play a limited role in the development of ESCC
and that mutation analysis is not useful as a screening test
for sensitivity to anti-EGFR therapy in ESCC.
Esophageal squamous cell carcinoma (ESCC) is the
major histological type of esophageal cancer in East Asian
countries and is one of the most aggressive malignant
tumors.1 Despite remarkable advances in multimodal
therapies, patient prognosis remains poor, even for those
whose carcinomas have been completely resected.2–5 The
limited improvement in treatment outcomes by conven-
tional therapies urged us to seek innovative strategies for
treating ESCC, especially those that are molecularly tar-
geted. One of the most promising targets is the inhibition of
the epidermal growth factor receptor (EGFR) by mono-
clonal antibodies (e.g., cetuximab, panitumumab) or small
molecule tyrosine kinase inhibitors (e.g., erlotinib, gefiti-
nib).6–10 The EGFR signal transduction network plays a
crucial role in multiple tumorigenic processes, contributing
to cell-cycle progression, angiogenesis, metastasis, and
protection of the cancer cell from apoptosis.11 Mutations in
the Kirsten Ras 1 (KRAS) and V-Raf Murine Sarcoma Viral
Oncogene Homolog B1 (BRAF) genes may be predictive of
response to drugs directly linked to the EGFR path-
way.12–14 Thus, molecular diagnosis of these mutations is
increasingly important in making therapeutic decisions.
Several previous studies have examined the frequency of
KRAS and BRAF mutations in ESCCs; however, they were
all limited by small sample sizes (all N B 80) (Table 1),
yielding inconclusive results.8,15–20
Pyrosequencing is a nonelectrophoretic nucleotide
extension sequencing technology for various applications,
including mutation testing of tumors.21–24 This technology
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has several advantages. First, it has higher sensitivity than
classical Sanger dideoxy sequencing.22 Sanger dideoxy
sequencing needs more than 20 % of tumor load in a speci-
men to render a reliable result, while pyrosequencing can
render a reliable result with a tumor load of 5 %. Second,
pyrosequencing is faster than Sanger dideoxy sequencing.
Third, pyrosequencing is more cost effective. Collectively,
pyrosequencing is a useful method in molecular diagnostics
and large-scale epidemiological studies.25,26
Therefore, in the present study, KRAS and BRAF
mutations were screened using a nonbiased database of 203
ESCCs and pyrosequencing technology.
PATIENTS AND METHODS
Study Subjects
A total of 217 consecutive patients with ESCC who
were undergoing curative resection at Kumamoto Univer-
sity Hospital between April 2005 and December 2010 were
enrolled in this study. There were 13 patients excluded
because of the unavailability of adequate tissue samples.
We initially quantified KRAS and BRAF mutation in 204
cancer specimens and obtained valid results in 203 cases
(99.5 %). Thus, 203 ESCCs were finally included in this
study. Tumor staging was done by the American Joint
Committee on Cancer Staging Manual (7th edition).27
Written informed consent was obtained from each subject,
and the institutional review board of Kumamoto University
approved the study procedures.
A total of 9 patients with colon cancers harboring 4 dif-
ferent KRAS mutations [c.35G[T (codon 12 GGT[GTT;
p.Gly12Val), c.35G[A (codon 12 GGT[GAT; p.Gly12Asp),
c.34G[T (codon 12 GGT[TGT; p.Gly12Cys), and c.38G[A
mutation (codon 13 GGC[GAC; p.Gly13Asp)], which had
been already diagnosed by Scorpion-ARMS technology, were
also included in this study to validate the pyrosequencing
method for the detection of KRAS mutations.
Genomic DNA Extraction
One pathologist marked the tumor areas on slides
stained with hematoxylin-eosin. Genomic DNA was
extracted from tumor lesions enriched with neoplastic cells,
without adjacent normal tissue, using an FFPE kit (Qiagen,
Valencia, CA). DNA was also extracted from 3 cell lines:
Colo201 and HT29 with the BRAF mutation c.1799T[A
(p.V600E), and HCT116 with wild-type BRAF using a
QIAmp DNA mini kit (Qiagen, Valencia, CA).28,29 DNA
was stored at -20 C before use.
Whole Genome Amplification
Whole genome amplification (WGA) is a useful tech-
nique for preserving original study material for many
different assays and for future studies. In WGA, genomic
DNA is amplified by polymerase chain reaction (PCR)
using primers consisting of a random sequence of 15
nucleotides. Each PCR mix contained 40 pmol of the
random primers, 1.0 nmol each of dNTP, 2.0 mmol/L
MgCl2, 19 PCR buffer (Applied Biosystems, Foster City,
CA), 0.25 U of AmpliTaq Gold 360 (Applied Biosystems),
and 5 ll of template DNA solution in a total volume of
50 ll. PCR conditions consisted of initial denaturation at
TABLE 1 Studies on KRAS







Studies on KRAS mutations in ESCC
Ma et al.15 35 Pyrosequencing 2 (5.7 %) Codons 12–13
Liu et al.16 50 Pyrosequencing 6 (12 %) Codons 12–13
Lorenzen et al.8 37 Direct sequencing 0 (0 %) Codons 12–13
Hollstein et al.17 16 Direct sequencing 0 (0 %) Codons 12–13
Victor et al.18 27 PCR and oligomer hybridization assay 0 (0 %) Codons 12–13
Hollstein et al.19 25 PCR and oligomer hybridization assay 0 (0 %) Codons 12–13
Present study 203 Pyrosequencing 1 (0.5 %) Codons 12–13
Studies on BRAF mutations in ESCC
Ma et al.15 35 Pyrosequencing 0 (0 %) Codon 600
Maeng et al.20 80 OncoMap 1 (1.2 %) Codon 600
Present study 203 Pyrosequencing 0 (0 %) Codon 600
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95 C for 10 min; 50 cycles of 95 C for 60 s, annealing
(37 C for 2 min), ramping from 37 to 55 C (0.1 C/s),
55 C for 2 min, and 68 C for 30 s; and a final extension
at 72 C for 7 min.
Pyrosequencing for KRAS and BRAF Mutations
Pyrosequencing technology has been shown to reliably
detect KRAS mutations with 100 % analytic sensitivity and
specificity, even when the proportion of mutant alleles is as low
as 10 %. PCR amplification primers for pyrosequencing tar-
geted for KRAS (codons 12, 13), BRAF (codon 600) were:
KRAS-F, forward, 50-NNNGGCCTGCTGAAAATGACT
GAA-30; and KRAS-R, reverse biotinylated primer, 50-TTA
GCTGTATCGTCAAGGCACTCT-30; and BRAF-F, for-
ward biotinylated primer, 50-CAGTAAAAATAGGTGATTT
TG-30; and BRAF-R reverse, 50-TCCAGACAACTGTTCAA
ACTGA-30. Each PCR mix contained the forward and reverse
primers (20 pmol each), 1.0 nmol of each dNTP with dUTP,
2 mmol/L MgCl2, 19 PCR buffer, 1.25 U of AmpliTaq Gold
360, 0.5 U of AmpErase UNG and 5 ll of template WGA
product in a total volume of 50 ll. PCR condition consisted of
initial denaturation at 50 C (10 min) for AmpErase UNG;
initial denaturation at 94 C (10 min) for AmpliTaq Gold 360;
50 cycles of 95 C (30 s), annealing (30 s; 55 C for BRAF,
57 C for KRAS), and 72 C (30 s); and a final extension at
72 C (7 min). The PCR products were electrophoresed
through an agarose gel to confirm successful amplification of
the 82-bp (KRAS) and the 80-bp PCR (BRAF) product.
KRAS and BRAF pyrosequencing was performed using the
PyroMark Q24 System (Qiagen, Valencia, CA) according to
the manufacturer’s instructions (Fig. 1 for KRAS; Fig. 2 for
BRAF). All forward sequencing results were confirmed by
reverse sequencing. In the KRAS pyrosequencing assay, the
presence of a mutation was routinely confirmed by 3 different
sequencing primers and by the creation of the frameshifted
open reading frame of the mutant sequence relative to a wild-
type sequence in a program. The primer KRAS-PF1 (50-
TGTGGTAGTTGGAGCTG-30; pyrosequencing nucleotide
dispensation order, ACTGATCG ATCGATCGATCGATC
GATCG) could detect the c.35G[T (codon 12 GTT) and
c.35G[A (codon 12 GAT) mutations. The primer KRAS-PF2
(50-TGTGGTAGTTGGAGCT-30; pyrosequencing nucleo-
tide dispensation order, ATCGATCGATCGATCGATCG
ATCATCG) could detect the c.34G[T (codon 12 TGT)
mutation. The primer KRAS-PF3 (50-TGGTAGTTGGAGC
TGGT-30; pyrosequencing nucleotide dispensation order,
GATGCATGCATGCATGCATGCATGCATGC) could
detect the c.34G[A (codon 13 GAC) mutation. In the BRAF
pyrosequencing assay, the primer was 50-CACTCCATC
GAGATTTC-30, and the pyrosequencing nucleotide dispen-
sation order was CTGCATGCATGCTGCA.
RESULTS
Clinical Data
A summary of the clinical characteristics of the patients
is given in Table 2. In this cohort, the 5-year overall sur-
vival rates of patients treated by esophagectomy were
83.9 % for stage I, 59.7 % for stage II, and 36.7 % for
stage III. These rates are similar to those from the
‘‘Comprehensive Registry of Esophageal Cancer in Japan’’
(79.5 % for stage I, 58.9 % for stage II, and 39.8 % for
stage III), which supports the absence of bias in our
database.30
Validation of the Pyrosequencing Assay for KRAS
Mutation Detection
We first examined the validity of the pyrosequencing
method using eleven colon cancer tissues harboring 4 different
KRAS mutations [c.35G[T (codon 12 GGT[GTT; p.Gly12-
Val), c.35G[A (codon 12 GGT[GAT; p.Gly12Asp),
c.34G[T (codon 12 GGT[TGT; p.Gly12Cys), and c.38G[A
mutation (codon 13 GGC[GAC; p.Gly13Asp)]. These
mutations had already been diagnosed by the sensitive Scor-
pion-ARMS technology [i.e., Amplification Refractory
Mutation System incorporating a unique bifunctional flores-
cent primer/probe molecule (Scorpion)]. As shown in
Table 3, all 4 types of mutations could be detected using the
pyrosequencing technology (11 of 11, 100 %) (Fig. 1), which
demonstrated that the method was reliable for the detection of
KRAS mutations in tumors.
KRAS Mutation in ESCC
Pyrosequence analysis of KRAS codon 12 and 13
mutations was successful for 203 of 204 (99.5 %) ESCC
paraffin-embedded tissues. Among the 203 ESCCs, only 1
case harbored a KRAS mutation [c.34G[T (codon 12
GGT[TGT; p.Gly12Cys)]. This mutation was also diag-
nosed by the Scorpion-ARMS technology (data not
shown). This result showed that the frequency of KRAS
mutations in ESCC was extremely low.
Validation of Pyrosequencing Assay for BRAF
Mutation Detection
To validate our BRAF pyrosequencing assay, both py-
rosequencing and Sanger dideoxy sequencing were
performed on the same set of DNA samples from 3 colon
cancer cell lines (HCT116, Colo201, and HT29). HCT116
possesses wild-type BRAF, and Colo201 and HT29 harbors
a BRAF mutation [c.1799T[A (p.V600E)]. In Sanger
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dideoxy sequencing, HCT116 showed was homozygous
wild-type for the BRAF gene, and HT29 and COLO201
were shown to be heterozygous BRAF V600E mutants
(Fig. 2). Among all 3 cell lines, pyrosequencing gave the









FIG. 1 Pyrograms of wild-type
and mutant KRAS in colorectal
carcinoma. a Wild-type codon 12
detected by the KRAS-PF1 primer.
b c.35GT (codon 12 GTT)
mutation detected by the KRAS-
PF1 primer. c c.35GA (codon 12
GAT) mutation detected by the
KRAS-PF1 primer. d Wild-type
codon 12 detected by the KRAS-
PF2 primer. e c.34GT (codon 12
TGT) mutation detected by the
KRAS-PF2 primer. f Wild-type
codon 13 detected by the KRAS-
PF3 primer. g c.38GA (codon 13
GAC) mutation detected by the
KRAS-PF3 primer. Arrows
indicate the presence of mutant
alleles
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Furthermore, the BRAF mutation could be detected in
paraffin-embedded tissues of colon cancer that had been
previously diagnosed by Sanger dideoxy sequencing. Col-
lectively, these preliminary experiments supported the
validity of the pyrosequencing method for the detection of
BRAF mutation in paraffin-embedded specimens.
BRAF Mutation in ESCC
The mutational status in BRAF exon 15 (V600E) was
examined in 204 ESCCs, and valid results were obtained in
203 tissues (99.5 %). All 203 ESCCs were wild-type at
codon 600 in BRAF exon 15.
DISCUSSION
KRAS and BRAF mutational status could represent a
predictive marker for anti-EGFR therapies; therefore, bet-
ter understanding of the incidence of these mutations is
important. However, the frequency of KRAS and BRAF
mutations in ESCCs remains inconclusive because of the
limited sample sizes of previous studies.8,15–20 The validity
of the pyrosequencing method for detecting KRAS and
BRAF mutations was initially demonstrated using colon
cancer cell lines and colon cancer tissues harboring KRAS
and BRAF mutations. Thereafter, KRAS mutations were
shown to be extremely rare in a database of more than 200
ESCCs. In addition, the BRAF mutation was absent in
ESCC tumors.
Pyrosequencing is a nonelectrophoretic nucleotide
extension sequencing technology that can be used for
mutation detection in tumors.21–24 Pyrosequencing offers a
higher sensitivity than classical Sanger dideoxy sequencing
for the detection of KRAS mutations.22 In addition, because
of its simplicity and cost effectiveness, pyrosequencing
represents a potentially useful method in molecular diag-
nostics and epidemiological studies, particularly in the
setting of large-scale projects and clinical assays.25,26
Mutations in the KRAS gene occur early in the devel-
opment of several types of cancers.31 Commonly restricted
to codon 12 and 13 in exon 2, these mutations cause
impaired GTPase activity and result in a continual stimulus
for cellular proliferation. They have been found in more
than 40 % of colorectal cancers, 90 % of pancreatic car-
cinomas, and 33 % of non-small-cell lung carcinomas.32
Importantly, KRAS mutation status has recently become an
important biomarker when identifying resistance to anti-
EGFR therapy. Several previous studies have examined the
frequency of KRAS mutations in ESCCs; only 2 studies
(N = 35 and 50) showed the presence of KRAS mutations
in ESCCs; however, others have demonstrated the absence
of KRAS mutation in ESCCs.8,15–19 Unfortunately, all
previous studies were limited by small sample sizes
(N B 80). It should be noted that small studies are more
FIG. 2 Detection of BRAF V600E in colon cancer cell lines by
dideoxy sequencing and pyrosequencing; detection of homozygous
wild type (HCT116), heterozygous mutant (HT29, COLO201). BRAF
V600E variants identified by dideoxy sequencing (left panel) and
pyrosequencing (right panel). The pyrosequencing nucleotide dis-
pensation order is shown below each pyrogram. The numerical
position for each nucleotide is indicated at the top. Arrows indicate
the presence of mutant alleles
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prone to ‘‘publication bias’’ than large studies. The phe-
nomenon of publication bias occurs because studies with
null findings (e.g., absence of KRAS mutation in tumors)
have a higher likelihood of being unwritten and unpub-
lished compared with those with significant results (e.g.,
presence of KRAS mutation in tumors). Compared with
small studies with null data, large studies with null data are
more likely to be published. As a result, large studies are
less prone to publication bias than small studies. Publishing
null data from well-powered studies are important because
publishing significant results from small underpowered
studies also leads to publication bias. In this respect, our
finding that KRAS mutations are extremely rare in a non-
biased database of more than 200 ESCCs may have
considerable implications.
The BRAF gene encodes a serine/threonine kinase of the
RAS RAF MEK MAPK signaling pathway and is mutated in
a variety of cancer types.33 The V600E point mutation in
exon 15 of the BRAF gene has been shown to be associated
with insensitivity to antigrowth signals, cell-cycle dysregu-
lation, tumor invasion and metastasis, escape from
apoptosis, unlimited replicative potential and angiogenesis,
and can be used as a predictive biomarker for BRAF-targeted
therapy. In addition, the prognostic role of the BRAF muta-
tion has been emphasized in several types of cancers.34–37
However, the incidence of the BRAF mutation in ESCC
remains less clear. One study showed the absence of a BRAF
mutation in 35 ESCCs, and the other showed that only 1
tumor harbored a BRAF mutation among 80 ESCC tumors.
In this study, the BRAF mutation was absent in 203 ESCCs.
In summary, KRAS mutations were extremely rare, and
the BRAF mutation was absent in a nonbiased database of
203 ESCCs. This suggests that KRAS and BRAF mutations
play a limited role in the development of ESCC and that
mutation analysis is not useful as a predictive marker for
sensitivity to anti-EGFR therapy in ESCC.
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